570 related articles for article (PubMed ID: 22301915)
1. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
2. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
6. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
7. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
8. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases.
Qu X; Wang M; Wang G; Han T; Mou C; Han L; Jiang M; Qu Y; Zhang M; Pang Q; Xu G
Eur J Endocrinol; 2011 Apr; 164(4):499-504. PubMed ID: 21252173
[TBL] [Abstract][Full Text] [Related]
9. Microprolactinomas in males treated by transsphenoidal surgery.
Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
[TBL] [Abstract][Full Text] [Related]
10. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
[No Abstract] [Full Text] [Related]
11. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
12. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
13. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
14. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas.
Tanaka S; Link MJ; Brown PD; Stafford SL; Young WF; Pollock BE
World Neurosurg; 2010 Jul; 74(1):147-52. PubMed ID: 21300006
[TBL] [Abstract][Full Text] [Related]
15. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
17. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
18. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
19. [Transsphenoidal surgery for prolactinomas: results and prognosis].
Sinkūnas K; Rastenyte D; Deltuva VP; Knispelis R; Tamasauskas A
Medicina (Kaunas); 2007; 43(9):691-7. PubMed ID: 17986841
[TBL] [Abstract][Full Text] [Related]
20. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]